Understanding Risk Factors for Progressive Chronic Kidney Disease in Malawi
NCT ID: NCT06312072
Last Updated: 2024-03-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
1100 participants
Study Classification
OBSERVATIONAL
Study Start Date
2024-02-14
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Worldwide, the number of people living with long-term health conditions, including chronic kidney disease (CKD), is increasing. CKD is usually asymptomatic in early stages but can progress to advanced disease, including kidney failure, causing significant morbidity and mortality.
In low-income countries of sub-Saharan Africa, including Malawi, treatments for kidney failure are not yet widely available and are prohibitively expensive . It is therefore vital to:
(a) Prevent development of CKD in the first place (b) Detect CKD earlier so that more cost-effective treatments can be given to slow progression.
There is little evidence on factors that drive CKD progression in Malawi, or on interventions that may be cost-effective for improving detection and slowing disease progression in this setting. This PhD will address these knowledge gaps, through the following aims:
1\) Determine the mortality associated with CKD, and the risk factors driving its development and progression in Malawian adults 2) Investigate the impacts of different models for integrating screening and prevention strategies for CKD and its risk factors into health services for other long-term conditions in low- and middle-income countries 3) With patients, carers, healthcare workers and policy makers, evaluate the feasibility and acceptability of different potential models for integrating CKD screening and prevention strategies into health services for high-risk patient groups in Malawi
In low-income countries of sub-Saharan Africa, including Malawi, treatments for kidney failure are not yet widely available and are prohibitively expensive . It is therefore vital to:
(a) Prevent development of CKD in the first place (b) Detect CKD earlier so that more cost-effective treatments can be given to slow progression.
There is little evidence on factors that drive CKD progression in Malawi, or on interventions that may be cost-effective for improving detection and slowing disease progression in this setting. This PhD will address these knowledge gaps, through the following aims:
1\) Determine the mortality associated with CKD, and the risk factors driving its development and progression in Malawian adults 2) Investigate the impacts of different models for integrating screening and prevention strategies for CKD and its risk factors into health services for other long-term conditions in low- and middle-income countries 3) With patients, carers, healthcare workers and policy makers, evaluate the feasibility and acceptability of different potential models for integrating CKD screening and prevention strategies into health services for high-risk patient groups in Malawi
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acceptability and Feasibility of Interventions for Integrated Care of Chronic Kidney Disease With Other Long-term Health Conditions in Malawi: a Qualitative Study
NCT06807567
Chronic Kidney Disease(CKD)
Multimorbidity
Long-term Health Conditions
NOT_YET_RECRUITING
Screening and Assessing the Risk Factors and Complications of Chronic Kidney Disease
NCT03246191
Chronic Kidney Disease
UNKNOWN
Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa
NCT05881447
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Arterial Hypertension
+8 more
RECRUITING
Impact of Specialised Renal Care in Patients With Chronic Kidney Disease
NCT00929760
Chronic Kidney Disease
COMPLETED
NA
Qualitative Study to Determine How Chronic Kidney Disease is Managed by Healthcare Professionals in Primary Care
NCT06024655
Chronic Kidney Diseases
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
CKD prevalence is rising most rapidly in sub-Saharan Africa (current estimates 13-15%), where health systems are least equipped to tackle it (1-7). Malawi has only one nephrologist for a population of over 19 million and kidney replacement therapy (KRT), which consumes disproportionate healthcare spending, remains extremely limited (8,9).
Historically there has been insufficient data on CKD in LMICs owing to difficulties accessing diagnostics and uncertainty regarding the most appropriate context-specific methods for estimating kidney function (10).
Recent research by the African Research on Kidney Disease (ARK) group using measured GFR has shown that previous creatinine-based estimates significantly underestimated CKD burden in many African countries; in Malawi prevalence of eGFR \<90ml/min/1.73m2 may be 51%, and eGFR \<60ml/min/1.73m2 as high as 11.9% (6).
CKD has many causes, impacting on the public health strategies required to tackle it; however data on its underlying causes in Malawi and other countries of low-income Africa remain limited.
Cross-sectional data suggests risk is greater in older people with other LTCs (e.g. hypertension, HIV), however other causes are unaccounted for (11-14). No longitudinal research has been conducted in Malawi to explore the impact of traditional and non-traditional risk factors on CKD development and progression.
Evidence on proteinuria in Malawi is also sparse, a well-recognised predictor for progressive kidney disease, cardiovascular morbidity and mortality (15-17) and a therapeutic target of drugs mitigating progression (18-22).
Early detection and prevention of CKD and its risk factors, integrated with other LTCs, is vital to cost-effectively improve health outcomes within available resources, as recognised by the Malawi government's National Action Plan for NCDs (23-25). To guide this, more research is urgently needed on the risk factors for CKD development and progression in this setting, and on strategies for early detection and prevention and that may be effectively integrated with public health plans for other LTCs, without reliance on specialist nephrology input.
Aims and Objectives:
The overall work package has three main aims:
Aim 1: Determine (a) the mortality associated with CKD, and (b) the risk factors driving its development and progression in Malawian adults
Aim 2: Investigate the impacts of different models for integrating screening and prevention strategies for CKD and its risk factors into health services for other LTCs in LMICs.
Aim 3: With different stakeholder groups, qualitatively evaluate the feasibility and acceptability of different potential models for integrating CKD screening and prevention strategies into health services for high-risk patient groups in Malawi
The work described here relates to observational research which aims to address Aim 1. The specific objectives within Aim 1 are as follows:
Aim 1, Objective 1:
In Malawian adults aged ≥18 years living in MEIRU's rural +/- urban population cohorts, investigate the association between baseline kidney function and mortality outcomes (all-cause and cause-specific)
Aim 1, Objective 2:
In adults aged ≥18 years living in MEIRU's rural and urban population cohorts, determine the risk factors associated with development of impaired kidney function
Aim 1, Objective 3:
In adults aged ≥18 years living in MEIRU's rural and urban population cohorts, determine the risk factors associated with progression of impaired kidney function
Planned methods for Aim 1:
The proposed work for Aim 1 is nested within MEIRU rural (Karonga HDSS) and urban (Area 25, Lilongwe) open, population-based cohorts. These nationally representative cohort populations (n\>50,000 adults ≥15 years) are situated in 135km2 of rural subsistence farming and fishing communities in northern Malawi and a township in the capital city. Population surveillance already includes annual censuses; births, deaths and migration registration, sociodemographic data and HIV-testing. This is ongoing in the rural cohort since 2002 and commenced in the urban cohort in 2022.26 For all deaths, a standardised WHO verbal autopsy (VA) tool is used to assign cause of death.
In both settings a comprehensive NCD survey was conducted 2013-2016. The currently ongoing Healthy Lives Malawi (HLM) survey is re-surveying long-term conditions (LTCs) in these populations. Available data from these two surveys includes household (SES, geolocators), interview (demographics, lifestyle factors, clinical history (prior diagnosis, screening and medications for chronic conditions), examination and measures (anthropometry, blood pressure, hand grip strength, peripheral arterial measures) and biological sample collection (serum, plasma and whole blood samples stored at -80 Celsius and other biological material).
Aim 1, objective 1
* Investigate the association between baseline kidney function and mortality outcomes (all-cause and cause-specific) in Malawian adults Study design
* Survival analysis using secondary data Study population
* Adults aged ≥18 years living within the demographic surveillance areas (Karonga HDSS +/- area 25, Lilongwe depending on availability of longitudinal data for the urban site), who participated in the 2013-16 NCD survey Approach and methods
* eGFRcreat and eGFRcystC will be calculated for adults living in the rural (+/- urban) site who have had serum creatinine (estimated n≥5000) +/- cystatin C (estimated n≥2500) tested on historical serum samples collected during their participation in the 2013-16 NCD survey, and for whom longitudinal demographic surveillance data is available
* Existing sociodemographic and comorbidity data will be available for these individuals
* Existing mortality data (physician assigned cause of death from verbal autopsy reports) will be analysed to for adults in different baseline eGFR categories
* Participants will be included until last point of follow-up
Aim 1, objective 2 - Investigate the risk factors for development of impaired kidney function in Malawian adults
Study design
* Retrospective cohort study Study population
* Adults aged ≥18 years living within the demographic surveillance areas (Karonga HDSS +/- area 25, Lilongwe), who had had eGFRcreat ≥60ml/min/1.73m2 during their participation in the 2013-16 NCD survey, and who have also participated in the follow-up 2022-25 LTC survey Approach and methods
* A sample of n=\~4000 adults with eGFRcreat ≥60ml/min/1.73m2 at baseline (2013-16) will be randomly selected within age and sex strata (these creatinine results are already available from which eGFR can be calculated)
* The participants will have already participated in the 2022-25 LTC survey; serum and plasma samples are collected for storage in this survey and participants provide consent for testing of these samples in future studies
* Creatinine will be tested on the 2022-25 LTC serum samples such that each participant has individual-level paired creatinine results from the two surveys
* Extensive sociodemographic and comorbidity data from both surveys already exists for all participants. These will be used to analyse associations between risk factors of interest and development of kidney disease outcome measures
Aim 1, Objective 3
* Investigate the risk factors for progression of impaired kidney function in Malawian adults Study design
* Prospective cohort study
Study population
\- Adults aged ≥18 years living within the demographic surveillance areas (Karonga HDSS +/- area 25, Lilongwe), with persistent eGFRcystC \<90ml/min/1.73m2 during their participation in both the 2013-16 NCD and 2022-25 LTC surveys
Approach and methods
An age-, sex- and site-stratified sample of n=1000-1100 adults with eGFRcystC \<90ml/min/1.73m2 at baseline (2013-16) will be selected (serum creatinine results will also be available for these individuals)
The participants will have already participated the 2022-25 LTC survey; serum and plasma samples are collected for storage in this survey and participants provide consent for testing of these in related and future studies.
Cystatin C and creatinine will be tested on the 2022-25 LTC serum samples such that each participant has individual-level paired kidney function results from the two previous surveys.
At ≥90 days following the LTC sample collection, a medical fieldworker will visit the household of each eligible participant to invite participation and consent (or assent) to participate in data collection for kidney disease and its risk factors, using standardised procedures for recording, collecting measurements and coding.
The data collected on kidney disease and its risk factors will include:
1. A medical interview, containing questions on potential risk factors for kidney disease not already captured in the LTC survey (specific medical history, specific medications, family history)
2. Health-related quality of life data
3. HIV rapid test and counselling will be offered to individuals with unknown HIV status
4. Venepuncture for blood tests - creatinine and cystatin C (taken ≥90 days after LTC sample, confirming chronicity) and for storage
5. Early morning mid-stream urine (MSU) collection - for point of care dipstick urinalysis, and laboratory tests, including microscopy, gram stain, filtration and centrifugation (for Schistosoma ova) and urine albumin-creatinine ratio (uACR).
The medical interview and health-related quality of life questionnaire data will be collected at the first household visit following the patient information and consent process; blood and urine samples will then be collected at a second, early morning household visit. Screening questions about menstruation (for females) and symptoms of urinary tract infection will be asked prior to scheduling the second household visit. Participants with symptoms of urine infection will be referred for clinical assessment. Participants with new urine symptoms or with particular urine dipstick abnormalities (leucocytes, nitrites and/or blood) at the point of urine collection at the second household visit will receive a third household visit for collection of a second, confirmatory urine sample.
Schistosoma IgG ELISA and CRP, new risk factors of interest, will be tested on participants' stored serum samples (from 2013-16).
Data on these new risk factors of interest will be analysed for association with kidney disease progression outcomes.
CKD prevalence is rising most rapidly in sub-Saharan Africa (current estimates 13-15%), where health systems are least equipped to tackle it (1-7). Malawi has only one nephrologist for a population of over 19 million and kidney replacement therapy (KRT), which consumes disproportionate healthcare spending, remains extremely limited (8,9).
Historically there has been insufficient data on CKD in LMICs owing to difficulties accessing diagnostics and uncertainty regarding the most appropriate context-specific methods for estimating kidney function (10).
Recent research by the African Research on Kidney Disease (ARK) group using measured GFR has shown that previous creatinine-based estimates significantly underestimated CKD burden in many African countries; in Malawi prevalence of eGFR \<90ml/min/1.73m2 may be 51%, and eGFR \<60ml/min/1.73m2 as high as 11.9% (6).
CKD has many causes, impacting on the public health strategies required to tackle it; however data on its underlying causes in Malawi and other countries of low-income Africa remain limited.
Cross-sectional data suggests risk is greater in older people with other LTCs (e.g. hypertension, HIV), however other causes are unaccounted for (11-14). No longitudinal research has been conducted in Malawi to explore the impact of traditional and non-traditional risk factors on CKD development and progression.
Evidence on proteinuria in Malawi is also sparse, a well-recognised predictor for progressive kidney disease, cardiovascular morbidity and mortality (15-17) and a therapeutic target of drugs mitigating progression (18-22).
Early detection and prevention of CKD and its risk factors, integrated with other LTCs, is vital to cost-effectively improve health outcomes within available resources, as recognised by the Malawi government's National Action Plan for NCDs (23-25). To guide this, more research is urgently needed on the risk factors for CKD development and progression in this setting, and on strategies for early detection and prevention and that may be effectively integrated with public health plans for other LTCs, without reliance on specialist nephrology input.
Aims and Objectives:
The overall work package has three main aims:
Aim 1: Determine (a) the mortality associated with CKD, and (b) the risk factors driving its development and progression in Malawian adults
Aim 2: Investigate the impacts of different models for integrating screening and prevention strategies for CKD and its risk factors into health services for other LTCs in LMICs.
Aim 3: With different stakeholder groups, qualitatively evaluate the feasibility and acceptability of different potential models for integrating CKD screening and prevention strategies into health services for high-risk patient groups in Malawi
The work described here relates to observational research which aims to address Aim 1. The specific objectives within Aim 1 are as follows:
Aim 1, Objective 1:
In Malawian adults aged ≥18 years living in MEIRU's rural +/- urban population cohorts, investigate the association between baseline kidney function and mortality outcomes (all-cause and cause-specific)
Aim 1, Objective 2:
In adults aged ≥18 years living in MEIRU's rural and urban population cohorts, determine the risk factors associated with development of impaired kidney function
Aim 1, Objective 3:
In adults aged ≥18 years living in MEIRU's rural and urban population cohorts, determine the risk factors associated with progression of impaired kidney function
Planned methods for Aim 1:
The proposed work for Aim 1 is nested within MEIRU rural (Karonga HDSS) and urban (Area 25, Lilongwe) open, population-based cohorts. These nationally representative cohort populations (n\>50,000 adults ≥15 years) are situated in 135km2 of rural subsistence farming and fishing communities in northern Malawi and a township in the capital city. Population surveillance already includes annual censuses; births, deaths and migration registration, sociodemographic data and HIV-testing. This is ongoing in the rural cohort since 2002 and commenced in the urban cohort in 2022.26 For all deaths, a standardised WHO verbal autopsy (VA) tool is used to assign cause of death.
In both settings a comprehensive NCD survey was conducted 2013-2016. The currently ongoing Healthy Lives Malawi (HLM) survey is re-surveying long-term conditions (LTCs) in these populations. Available data from these two surveys includes household (SES, geolocators), interview (demographics, lifestyle factors, clinical history (prior diagnosis, screening and medications for chronic conditions), examination and measures (anthropometry, blood pressure, hand grip strength, peripheral arterial measures) and biological sample collection (serum, plasma and whole blood samples stored at -80 Celsius and other biological material).
Aim 1, objective 1
* Investigate the association between baseline kidney function and mortality outcomes (all-cause and cause-specific) in Malawian adults Study design
* Survival analysis using secondary data Study population
* Adults aged ≥18 years living within the demographic surveillance areas (Karonga HDSS +/- area 25, Lilongwe depending on availability of longitudinal data for the urban site), who participated in the 2013-16 NCD survey Approach and methods
* eGFRcreat and eGFRcystC will be calculated for adults living in the rural (+/- urban) site who have had serum creatinine (estimated n≥5000) +/- cystatin C (estimated n≥2500) tested on historical serum samples collected during their participation in the 2013-16 NCD survey, and for whom longitudinal demographic surveillance data is available
* Existing sociodemographic and comorbidity data will be available for these individuals
* Existing mortality data (physician assigned cause of death from verbal autopsy reports) will be analysed to for adults in different baseline eGFR categories
* Participants will be included until last point of follow-up
Aim 1, objective 2 - Investigate the risk factors for development of impaired kidney function in Malawian adults
Study design
* Retrospective cohort study Study population
* Adults aged ≥18 years living within the demographic surveillance areas (Karonga HDSS +/- area 25, Lilongwe), who had had eGFRcreat ≥60ml/min/1.73m2 during their participation in the 2013-16 NCD survey, and who have also participated in the follow-up 2022-25 LTC survey Approach and methods
* A sample of n=\~4000 adults with eGFRcreat ≥60ml/min/1.73m2 at baseline (2013-16) will be randomly selected within age and sex strata (these creatinine results are already available from which eGFR can be calculated)
* The participants will have already participated in the 2022-25 LTC survey; serum and plasma samples are collected for storage in this survey and participants provide consent for testing of these samples in future studies
* Creatinine will be tested on the 2022-25 LTC serum samples such that each participant has individual-level paired creatinine results from the two surveys
* Extensive sociodemographic and comorbidity data from both surveys already exists for all participants. These will be used to analyse associations between risk factors of interest and development of kidney disease outcome measures
Aim 1, Objective 3
* Investigate the risk factors for progression of impaired kidney function in Malawian adults Study design
* Prospective cohort study
Study population
\- Adults aged ≥18 years living within the demographic surveillance areas (Karonga HDSS +/- area 25, Lilongwe), with persistent eGFRcystC \<90ml/min/1.73m2 during their participation in both the 2013-16 NCD and 2022-25 LTC surveys
Approach and methods
An age-, sex- and site-stratified sample of n=1000-1100 adults with eGFRcystC \<90ml/min/1.73m2 at baseline (2013-16) will be selected (serum creatinine results will also be available for these individuals)
The participants will have already participated the 2022-25 LTC survey; serum and plasma samples are collected for storage in this survey and participants provide consent for testing of these in related and future studies.
Cystatin C and creatinine will be tested on the 2022-25 LTC serum samples such that each participant has individual-level paired kidney function results from the two previous surveys.
At ≥90 days following the LTC sample collection, a medical fieldworker will visit the household of each eligible participant to invite participation and consent (or assent) to participate in data collection for kidney disease and its risk factors, using standardised procedures for recording, collecting measurements and coding.
The data collected on kidney disease and its risk factors will include:
1. A medical interview, containing questions on potential risk factors for kidney disease not already captured in the LTC survey (specific medical history, specific medications, family history)
2. Health-related quality of life data
3. HIV rapid test and counselling will be offered to individuals with unknown HIV status
4. Venepuncture for blood tests - creatinine and cystatin C (taken ≥90 days after LTC sample, confirming chronicity) and for storage
5. Early morning mid-stream urine (MSU) collection - for point of care dipstick urinalysis, and laboratory tests, including microscopy, gram stain, filtration and centrifugation (for Schistosoma ova) and urine albumin-creatinine ratio (uACR).
The medical interview and health-related quality of life questionnaire data will be collected at the first household visit following the patient information and consent process; blood and urine samples will then be collected at a second, early morning household visit. Screening questions about menstruation (for females) and symptoms of urinary tract infection will be asked prior to scheduling the second household visit. Participants with symptoms of urine infection will be referred for clinical assessment. Participants with new urine symptoms or with particular urine dipstick abnormalities (leucocytes, nitrites and/or blood) at the point of urine collection at the second household visit will receive a third household visit for collection of a second, confirmatory urine sample.
Schistosoma IgG ELISA and CRP, new risk factors of interest, will be tested on participants' stored serum samples (from 2013-16).
Data on these new risk factors of interest will be analysed for association with kidney disease progression outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Chronic Kidney Diseases
Non-Communicable Chronic Diseases
Non-communicable Disease
Kidney Diseases
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MEIRU rural population cohort
Adults aged \>=18 living in MEIRU's rural health demographic surveillance area (Karonga district)
No interventions to be administered; observational study only, with collection of survey data, blood samples and urine samples.
No intervention; observational study
Intervention Type
OTHER
No intervention; observational study
MEIRU urban population cohort
Adults aged \>=18 living in MEIRU's urben demographic surveillance area (Lilongwe Area 25)
No interventions to be administered; observational study only, with collection of survey data, blood samples and urine samples.
No intervention; observational study
Intervention Type
OTHER
No intervention; observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention; observational study
No intervention; observational study
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult ≥ 18 years at time of participation in 2013-16 NCD survey
* Living in one of the demographic surveillance sites (Chilumba, Karonga or Lilongwe area 25)
* Creatinine +/- cystatin C result available from serum sample taken in 2013-16 NCD survey
* eGFRcreat ≥60ml/min/1.73m3 at baseline (using creatinine tested on serum sample from 2013-16 survey)
* Participated and provided blood (serum) sample in 2022-25 long-term conditions (LTC) survey i.e. individual-level longitudinal paired serum samples available, including consent already given for testing of stored samples in future studies
As for Objective 1, PLUS:
* eGFRcystC \<90ml/min/1.73m3 at baseline (using cystatin C tested on 2013-16 serum sample)
* Participated and provided serum sample in 2022-25 long-term conditions (LTC) survey i.e. individual-level longitudinal paired serum samples available
* Still alive and living in one of the demographic surveillance sites
* Able to provide consent or assent with consent from an appropriate nominated guardian
Exlusion criteria:
* Declines consent
* Unable to consent or assent
* Children (\<18 years)
* Non-resident in study areas
* Acute physical or mental illness
* Hospital inpatient
* Hospital admission \>24 hours in past 90 days and \<90 days until study end
* Currently pregnant
* Living in one of the demographic surveillance sites (Chilumba, Karonga or Lilongwe area 25)
* Creatinine +/- cystatin C result available from serum sample taken in 2013-16 NCD survey
* eGFRcreat ≥60ml/min/1.73m3 at baseline (using creatinine tested on serum sample from 2013-16 survey)
* Participated and provided blood (serum) sample in 2022-25 long-term conditions (LTC) survey i.e. individual-level longitudinal paired serum samples available, including consent already given for testing of stored samples in future studies
As for Objective 1, PLUS:
* eGFRcystC \<90ml/min/1.73m3 at baseline (using cystatin C tested on 2013-16 serum sample)
* Participated and provided serum sample in 2022-25 long-term conditions (LTC) survey i.e. individual-level longitudinal paired serum samples available
* Still alive and living in one of the demographic surveillance sites
* Able to provide consent or assent with consent from an appropriate nominated guardian
Exlusion criteria:
* Declines consent
* Unable to consent or assent
* Children (\<18 years)
* Non-resident in study areas
* Acute physical or mental illness
* Hospital inpatient
* Hospital admission \>24 hours in past 90 days and \<90 days until study end
* Currently pregnant
Exclusion Criteria
* Child (age \<18 years)
* Not living in one of the study areas
Aim 1, Objective 2 (retrospective cohort study)
* Child (age \<18 years)
* Not living in one of the study areas
* Not consented previously to storage of blood samples and use of samples in future studies
Aim 1, Objective 3
* Not living in one of the study areas
Aim 1, Objective 2 (retrospective cohort study)
* Child (age \<18 years)
* Not living in one of the study areas
* Not consented previously to storage of blood samples and use of samples in future studies
Aim 1, Objective 3
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wellcome Trust
OTHER
Sponsor Role
collaborator
Malawi Epidemiology and Intervention Research Unit
OTHER
Sponsor Role
collaborator
London School of Hygiene and Tropical Medicine
OTHER
Sponsor Role
collaborator
University of Glasgow
OTHER
Sponsor Role
collaborator
Malawi-Liverpool-Wellcome Trust Clinical Research Programme
OTHER
Sponsor Role
collaborator
Liverpool School of Tropical Medicine
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charlotte Snead, BM BCh
Role: PRINCIPAL_INVESTIGATOR
Liverpool School of Tropical Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Malawi Epidemiology and Intervention Research Unit
Chilumba, Karonga, Malawi
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Malawi
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020 Feb 29;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3. Epub 2020 Feb 13.
Reference Type
BACKGROUND
Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Kottgen A, Levey AS, Levin A. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013 Jul 13;382(9887):158-69. doi: 10.1016/S0140-6736(13)60439-0. Epub 2013 May 31.
Reference Type
BACKGROUND
Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJL, Jardine M, Kasiske B, Kottgen A, Kretzler M, Levey AS, Luyckx VA, Mehta R, Moe O, Obrador G, Pannu N, Parikh CR, Perkovic V, Pollock C, Stenvinkel P, Tuttle KR, Wheeler DC, Eckardt KU; ISN Global Kidney Health Summit participants. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017 Oct 21;390(10105):1888-1917. doi: 10.1016/S0140-6736(17)30788-2. Epub 2017 Apr 20.
Reference Type
BACKGROUND
Stanifer JW, Jing B, Tolan S, Helmke N, Mukerjee R, Naicker S, Patel U. The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2014 Mar;2(3):e174-81. doi: 10.1016/S2214-109X(14)70002-6. Epub 2014 Feb 10.
Reference Type
BACKGROUND
Kaze AD, Ilori T, Jaar BG, Echouffo-Tcheugui JB. Burden of chronic kidney disease on the African continent: a systematic review and meta-analysis. BMC Nephrol. 2018 Jun 1;19(1):125. doi: 10.1186/s12882-018-0930-5.
Reference Type
BACKGROUND
Fabian J, Kalyesubula R, Mkandawire J, Hansen CH, Nitsch D, Musenge E, Nakanga WP, Prynn JE, Dreyer G, Snyman T, Ssebunnya B, Ramsay M, Smeeth L, Tollman S, Naicker S, Crampin A, Newton R, George JA, Tomlinson L; African Research on Kidney Disease Consortium. Measurement of kidney function in Malawi, South Africa, and Uganda: a multicentre cohort study. Lancet Glob Health. 2022 Aug;10(8):e1159-e1169. doi: 10.1016/S2214-109X(22)00239-X.
Reference Type
BACKGROUND
Luyckx VA, Moosa MR. Priority Setting as an Ethical Imperative in Managing Global Dialysis Access and Improving Kidney Care. Semin Nephrol. 2021 May;41(3):230-241. doi: 10.1016/j.semnephrol.2021.05.004.
Reference Type
BACKGROUND
Dreyer G, Dobbie H, Banks R, Allain T, Gonani A, Turner NLV. Supporting Malawi's dialysis services in the international community. Br J Ren Med. 2012;17:24-6.
Reference Type
BACKGROUND
https://www.theisn.org/blog/2014/11/24/caring-for-kidney-patients-in-malawi/
Reference Type
BACKGROUND
Fabian J, George JA, Etheredge HR, van Deventer M, Kalyesubula R, Wade AN, Tomlinson LA, Tollman S, Naicker S. Methods and reporting of kidney function: a systematic review of studies from sub-Saharan Africa. Clin Kidney J. 2019 Aug 19;12(6):778-787. doi: 10.1093/ckj/sfz089. eCollection 2019 Dec.
Reference Type
BACKGROUND
Nakanga WP, Prynn JE, Banda L, Kalyesubula R, Tomlinson LA, Nyirenda M, Crampin AC. Prevalence of impaired renal function among rural and urban populations: findings of a cross-sectional study in Malawi. Wellcome Open Res. 2019 Jun 10;4:92. doi: 10.12688/wellcomeopenres.15255.1. eCollection 2019.
Reference Type
BACKGROUND
Muiru AN, Charlebois ED, Balzer LB, Kwarisiima D, Elly A, Black D, Okiror S, Kabami J, Atukunda M, Snyman K, Petersen M, Kamya M, Havlir D, Estrella MM, Hsu CY. The epidemiology of chronic kidney disease (CKD) in rural East Africa: A population-based study. PLoS One. 2020 Mar 4;15(3):e0229649. doi: 10.1371/journal.pone.0229649. eCollection 2020.
Reference Type
BACKGROUND
Kalyesubula R, Nankabirwa JI, Ssinabulya I, Siddharthan T, Kayima J, Nakibuuka J, Salata RA, Mondo C, Kamya MR, Hricik D. Kidney disease in Uganda: a community based study. BMC Nephrol. 2017 Apr 3;18(1):116. doi: 10.1186/s12882-017-0521-x.
Reference Type
BACKGROUND
Stanifer JW, Maro V, Egger J, Karia F, Thielman N, Turner EL, Shimbi D, Kilaweh H, Matemu O, Patel UD. The epidemiology of chronic kidney disease in Northern Tanzania: a population-based survey. PLoS One. 2015 Apr 17;10(4):e0124506. doi: 10.1371/journal.pone.0124506. eCollection 2015.
Reference Type
BACKGROUND
Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int Suppl. 1997 Dec;63:S54-7.
Reference Type
BACKGROUND
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995 Nov 15;123(10):754-62. doi: 10.7326/0003-4819-123-10-199511150-00003.
Reference Type
BACKGROUND
Agrawal V, Marinescu V, Agarwal M, McCullough PA. Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nat Rev Cardiol. 2009 Apr;6(4):301-11. doi: 10.1038/nrcardio.2009.11.
Reference Type
BACKGROUND
Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997 Jun 21;349(9068):1787-92.
Reference Type
BACKGROUND
Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol. 2001 Dec;12(12):2832-2837. doi: 10.1681/ASN.V12122832.
Reference Type
BACKGROUND
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
Reference Type
BACKGROUND
Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
Reference Type
BACKGROUND
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4.
Reference Type
BACKGROUND
Okpechi IG, Bello AK, Ameh OI, Swanepoel CR. Integration of Care in Management of CKD in Resource-Limited Settings. Semin Nephrol. 2017 May;37(3):260-272. doi: 10.1016/j.semnephrol.2017.02.006.
Reference Type
BACKGROUND
World Health Organization. Strengthening Health Systems to Improve Health Outcomes. https://www.who.int/healthsystems/ strategy/en/. 2007. Accessed February 26, 2021
Reference Type
BACKGROUND
Commission NP. The Malawi Noncommunicable Diseases & Injuries Poverty Commission Report. Lilongwe: Malawi Ministry of Health, 2018. http://www.ncdipoverty.org/malawi-report
Reference Type
BACKGROUND
Crampin AC, Dube A, Mboma S, Price A, Chihana M, Jahn A, Baschieri A, Molesworth A, Mwaiyeghele E, Branson K, Floyd S, McGrath N, Fine PE, French N, Glynn JR, Zaba B. Profile: the Karonga Health and Demographic Surveillance System. Int J Epidemiol. 2012 Jun;41(3):676-85. doi: 10.1093/ije/dys088. Epub 2012 Jun 22.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa
NCT03458338
COMPLETED
Factors Influencing Risk of Progression of Chronic Kidney Disease
NCT03954470
COMPLETED
Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease
NCT02509013
UNKNOWN
Assessment of Protein Intake Using 2 Types of Nutritional Collection in Chronic Kidney Disease.
NCT06224153
RECRUITING
Impact on Mortality of Screening for Kidney Disease Associated With a Specialized Intervention During Hospitalization in a Territorial Hospital Trust
NCT05033652
UNKNOWN
NA
Community-based Screening of Chronic Kidney Disease (CKD) and Measure the Impact of Health Education
NCT04094831
UNKNOWN
NA
Effects of a Reduction in Renal Function on Cardiovascular Structure and Function
NCT02973607
COMPLETED
Proteinuria in Renal Transplant Patients Treated with Dapagliflozin
NCT06165601
RECRUITING
NA
Chronic Kidney Disease: Determinants of Progression and Cardiovascular Risk
NCT03393663
COMPLETED
Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD)
NCT01415570
UNKNOWN
Chronic Kidney Disease Registry Platform Study
NCT06117852
RECRUITING
What Are the Determinations of Adult Progressive CKD? The Renal Impairment In Secondary Care (RIISC) Study
NCT01722383
ACTIVE_NOT_RECRUITING
Effectiveness of Integrated Care on Delaying Chronic Kidney Disease Progression in Rural Communities of Thailand
NCT01978951
COMPLETED
NA
Effects of a Reduction in Kidney Function on Cardiovascular Structure and Function: A Prospective Study of Kidney Donors
NCT01028703
COMPLETED
Non Diabetic Causes of Chronic Kidney Disease in Type 2 Diabetic Patients
NCT05021705
COMPLETED
Integrating Risk-based Care for Patients With CKD
NCT03365063
TERMINATED
NA
A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria
NCT05967806
COMPLETED
Cohort Follow-up: Progression and Consequences of Chronic Kidney Disease.
NCT04070885
COMPLETED
Percutaneous Nephrolithotomy in Patients With Stage 2-4 Chronic Kidney Disease
NCT04943081
UNKNOWN
NA
PREDICT: Thinking About Pregnancy Risk in Women With Kidney Disease
NCT04370769
UNKNOWN
Detection and Management of Acute Kidney Injury (AKI) in Low and Low Middle Income Countries: A Pilot Feasibility Project
NCT02912611
COMPLETED
NA
Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
NCT05476627
RECRUITING
Prevention In Community Clinics From Diabetic Kidney Disease
NCT04988581
UNKNOWN
NA
Competing Risk of Death and ESRD in Incident CKD Patients
NCT03379571
COMPLETED
Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis
NCT03126201
COMPLETED